Mu Feng, CEO of MGI and Zhou Jun, CEO of Berry Oncology
Shenzhen, China, 27 March 2023 – MGI and Berry Oncology Co., Ltd. (hereinafter referred to as “Berry Oncology”) have officially signed a strategic cooperation agreement. Under the agreement, MGI will provide its DNBSEQ sequencing platforms and automation systems to support Berry Oncology’s early cancer screening efforts, as well as the registration and regulatory submission of companion diagnostic products. The partnership aims to accelerate the high-quality development of precision cancer diagnosis and treatment.
MGI and Berry Oncology Join Forces to Advance Precision Cancer Diagnosis and Treatment
Mu Feng, CEO of MGI, and Zhou Jun, CEO of Berry Oncology: “We are pleased to partner with MGI to drive deeper, broader and more sustainable innovation in early cancer screening technologies and products,” said Zhou Jun, CEO of Berry Oncology. “This collaboration brings together leading technologies and platforms from both companies to advance precision cancer diagnosis and treatment, ensuring our products and technologies serve patients and deliver real-world benefits.”
“As a leading provider of core life science tools and technologies, MGI is committed to building an open and collaborative ecosystem for clinical and scientific research users across the value chain,” said Mu Feng, CEO of MGI. “Over the past six years, we have developed a comprehensive portfolio of sequencing products spanning low, medium and high throughput, while reducing sequencing costs to below USD 100. We look forward to working closely with Berry Oncology to achieve mutually beneficial growth, drive meaningful breakthroughs in oncology and precision medicine and support the continued advancement of genomics.”
High-throughput sequencing technology is now widely used in early cancer and multi-cancer screening. As one of only two companies globally capable of independently developing and mass-producing low-, medium- and high-throughput clinical gene sequencers, ranging from gigabase to terabase scale, MGI offers a broad product portfolio that supports diverse applications with high-quality data output at competitive cost.
Berry Oncology is a global leader in genetic testing and early cancer screening. This strategic collaboration will support the development of a full lifecycle product pipeline for precision cancer diagnosis and treatment, while further improving the availability and accessibility of effective cancer screening services.
